Diaorigin Biotechnology

DIAORIGIN BIOTECHNOLOGY - EXCELLENCE FOR IN VITRO DIAGNOSTIC RESEARCH

In March 2020, Diaorigin created its research lab in Shanghai by the founder of Larix Bioscience, Dr. Bo YU, patent holder of SwiMR, a high-performance technology for construction of high-expression cell lines. In December 2020, Diaorigin head-quartered in Paris, headed by Dr. Yongjin WANG, former researcher from the Institut Pasteur.

In September 2020, Diaorigin signed a partnership agreement with Rapid Novor, the whole protein sequencing expert. Thanks to the combination with the high performance of our SwiMR technology, Diaorigin is capable of reproducing all known antigens and antibodies in large quantities, in saving more than 50% of the production cost for pharmaceutical manufacturers. More than 300 projects of antigen and antibody reproduction have been executed since September 2020.

Diaorigin develops and commercializes its own antigen and antibody products for all infectious, carcinogenic and autoimmune diseases for research laboratories and pharmaceutical industry. Hundreds of the antigens and antibodies are already commercialized.

With our reproduction platform for antigen and antibody, the most important raw materials for in vitro diagnostic industry, Diaorigin provides full-scale development services for our customers for all in vitro medical diagnostic devices, especially for innovative tests.

Our expertises :

- Construction of high-expression cell lines;

- Production of industrial antigens and antibodies;

- Developpement of innovative in vitro diagnostic devices.

Applied in the medical industry for more than nine years by Larix Bioscience, the SwiMR technology can revolutionize the in vitro diagnostic industry for several reasons :

- Reduce at least 50% of the production cost for the raw materials (antigens and antibodies);

- Save at least half of the development time (4-8 months with current systems versus 1-4 months with SwiMR technology);

- More stable than current expression systems;

- Non-pressure selection minimizes mutations;

- An easy-to-use technology applicable to all types of cells.

New: SARS-CoV-2 Anti-Spike Antibody Rapid Test

- by fluorescence immuno-chromatography assay-

Faced with successive waves of the Covid-19 pandemic, the campaign vaccination is at the center of the arsenal to fight the virus, with the goal of achieving herd immunity.

Clinical studies show that immunity against Covid decreases over time and differs from person to person. Vaccination or infection, age, gender, parameters not yet listed: so many diverse factors at the subject of the duration of immunity, it seems judicious to change the prism and opt for a case-by-case approach.

Scientific studies have defined that an anti-Spike antibody level of 260 BAU/ml can provide 80% protection against Covid-19. The French Ministry of Health (HAS) have recommended that immuno-compromised patients who have received a complete vaccination, but with an anti-Spike antibody level below 260 BAU/ml, are considered as “poorly responders” with the risk to be insufficiently protected. According to clinical studies, vaccinated people who do not have sufficient immunity are more likely to be infected and to develop serious forms.

The purpose of this test is to distinguish the population that no longer has sufficient immunity, and to inform these individuals so that they adopt reinforced means to protect themselves, by strengthening the respect for barrier gestures and possibly by anticipating the revaccination. This tool would contribute to achieving herd immunity, to better orient the vaccination campaign, to relieve the pressure hospital, and to develop next-generation vaccines more efficient.

One drop of blood, Results in 15 min, Reliability 99.2%.